Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ImmunityBio, Inc.

< Previous 1 2 3 4 Next >
News headline image
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
News headline image
ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma
From ImmunityBio, Inc.
Via Business Wire
Tickers IBRX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.